Common genetic variations of the renin-angiotensin-aldosterone system and response to acute angiotensin I-converting enzyme inhibition in essential hypertension

Journal of Hypertension

Volumn 28, Issue 4, 2010, Pages 771-779

  Hannila Handelberg, Tuula ^a   Kontula, Kimmo K ^a   Paukku, Kirsi ^a   Lehtonen, Jukka Y ^a   Virtamo, Jarmo ^b   Tikkanen, Ilkka ^a   Hiltunen, Timo P ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

Aldosterone; Angiotensin receptor; Captopril; Hypertension; Rennin

Indexed keywords

ALDOSTERONE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSINOGEN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; RENIN;

ADULT; ALDOSTERONE BLOOD LEVEL; ARTICLE; BLOOD PRESSURE; ENZYME INHIBITION; ESSENTIAL HYPERTENSION; FEMALE; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT RESPONSE;

EID: 77954039271     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328335c368     Document Type: Article

References (41)

1. Hiltunen TP, Suonsyrja T, Hannila-Handelberg T, Paavonen KJ, Miettinen HE, Strandberg T, et al. Predictors of antihypertensive drug responses: initial data from a placebo-controlled, randomized, cross-over study with four antihypertensive drugs (the GENRES study). Am J Hypertens 2007; 20:311-318.
2. Chapman AB, Schwartz GL, Boerwinkle E, Turner ST. Predictors of antihypertensive response to a standard dose of hydrochlorothiazide for essential hypertension. Kidney Int 2002; 61:1047-1055.
3. Suonsyrja T, Hannila-Handelberg T, Paavonen KJ, Miettinen HE, Donner K, Strandberg T, et al. Laboratory tests as predictors of the antihypertensive effects of amlodipine, bisoprolol, hydrochlorothiazide and losartan in men: Results from the randomized, double-blind, crossover GENRES study. J Hypertens 2008; 26:1250-1256.
4. Arnett DK, Claas SA, Glasser SP. Pharmacogenetics of antihypertensive treatment. Vascul Pharmacol 2006; 44:107-118.
5. Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. Cell 2001; 104:545-556.
6. Hannila-Handelberg T, Kontula K, Tikkanen I, Tikkanen T, Fyhrquist F, Helin K, et al. Common variants of the beta and gamma subunits of the epithelial sodium channel and their relation to plasma renin and aldosterone levels in essential hypertension. BMC Med Genet 2005; 6:4.
7. Seifarth C, Trenkel S, Schobel H, Hahn EG, Hensen J. Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism. Clin Endocrinol (Oxf) 2002; 57:457-465.
8. Muller FB, Sealey JE, Case DB, Atlas SA, Pickering TG, Pecker MS, et al. The captopril test for identifying renovascular disease in hypertensive patients. Am J Med 1986; 80:633-644.
9. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med 1994; 330:1029-1035.
10. Kainulainen K, Perola M, Terwilliger J, Kaprio J, Koskenvuo M, Syvanen AC, et al. Evidence for involvement of the type 1 angiotensin II receptor locus in essential hypertension. Hypertension 1999; 33:844-849.
11. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86:1343-1346.
12. Shanmugam V, Sell KW, Saha BK. Mistyping ACE heterozygotes. PCR Methods Appl 1993; 3:120-121.
13. Russ AP, Maerz W, Ruzicka V, Stein U, Gross W. Rapid detection of the hypertension-associated Met235-> Thr allele of the human angiotensinogen gene. Hum Mol Genet 1993; 2:609-610.
14. Lasky-Su J, Lyon HN, Emilsson V, Heif IM, Molony C, Raby BA, et al. On the replication of genetic associations: timing can be everything!. Am J Hum Genet 2008; 82:849-858.
15. Turner ST, Schwartz GL, Chapman AB, Hall WD, Boerwinkle E. Antihypertensive pharmacogenetics: getting the right drug into the right patient. J Hypertens 2001; 19:1-11.
16. Mellen PB, Herrington DM. Pharmacogenomics of blood pressure response to antihypertensive treatment. J Hypertens 2005; 23:1311-1325.
17. Nakano Y, Oshima T, Watanabe M, Matsuura H, Kajiyama G, Kambe M. Angiotensin I-converting enzyme gene polymorphism and acute response to captopril in essential hypertension. Am J Hypertens 1997; 10:1064-1068.
18. Todd GP, Chadwick IG, Higgins KS, Yeo WW, Jackson PR, Ramsay LE. Relation between changes in blood pressure and serum ACE activity after a single dose of enalapril and ACE genotype in healthy subjects. Br J Clin
19. Mondorf UF, Russ A, Wiesemann A, Herrero M, Oremek G, Lenz T. Contribution of angiotensin I converting enzyme gene polymorphism and angiotensinogen gene polymorphism to blood pressure regulation in essential hypertension. Am J Hypertens 1998; 11:174-183.
20. Miller JA, Thai K, Scholey JW. Angiotensin II type 1 receptor gene polymorphism predicts response to losartan and angiotensin II. Kidney Int 1999; 56:2173-2180
21. Spiering W, Kroon AA, Fuss-Lejeune MJ, de Leeuw PW. Genetic contribution to the acute effects of angiotensin II type 1 receptor blockade. J Hypertens 2005; 23:753-758.
22. Benetos A, Cambien F, Gautier S, Ricard S, Safar M, Laurent S, et al. Influence of the angiotensin II type 1 receptor gene polymorphism on the effects of perindopril and nitrendipine on arterial stiffness in hypertensive individuals. Hypertension 1996; 28:1081-1084. (Pubitemid 26415828)
23. Hingorani AD, Jia H, Stevens PA, Hopper R, Dickerson JE, Brown MJ. Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition. J Hypertens 1995; 13:1602-1609.
24. Yu H, Lin S, Jin L, Yu Y, Zhong J, Zhang Y, Liu G. Adenine/cytosine1166 polymorphism of the angiotensin II type 1 receptor gene and the antihypertensive response to angiotensin-converting enzyme inhibitors. J Hypertens 2009; 27:2278-2282.
25. Kurland L, Melhus H, Karlsson J, Kahan T, Malmqvist K, Ohman KP, et al. Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients. J Hypertens 2001; 19:1783-1787.
26. Suonsyrjä T, Hannila-Handelberg T, Fodstad H, Donner K, Kontula K, Hiltunen TP. Renin-angiotensin system and alpha-adducin gene polymorphisms, and their relation to responses to antihypertensive drugs: results from the GENRES Study. Am J Hypertens 2009; 22:169- 175.
27. Li X, Du Y, Du Y, Huang X. Correlation of angiotensin-conrerting enzyme gene polymorphism with effect of antihypertensive therapy by angiotensinconverting enzyme inhibitor. J Cardiovasc Pharmacol Ther 2003; 8:25-30.
28. Stavroulakis GA, Makris TK, Krespi PG, Hatzizacharias AN, Gialeraki AE, Anastasiadis G, et al. Predicting response to chronic antihypertensive treatment with fosinopril: the role of angiotensin-converting enzyme gene polymorphism. Cardiovasc Drugs Ther 2000; 14:427-432.
29. Ohmichi N, Iwai N, Uchida Y, Shichiri G, Nakamura Y, Kinoshita M. Relationship between the response to the angiotensin converting enzyme inhibitor imidapril and the angiotensin converting enzyme genotype. Am J Hypertens 1997; 10:951-955.
30. Haas M, Yilmaz N, Schmidt A, Neyer U, Arneitz K, Stummvoll HK, et al. Angiotensin-converting enzyme gene polymorphism determines the antiproteinuric and systemic hemodynamic effect of enalapril in patients with proteinuric renal disease. Austrian study group of the effects of enalapril treatment in proteinuric renal disease. Kidney Blood Press Res 1998; 21:66-69.
31. O'Toole L, Stewart M, Padfield P, Channer K. Effect of the insertion deletion polymorphism of the angiotensin-converting enzyme gene on response to angiotensin-converting enzyme inhibitors in patients with heart failure. J Cardiovasc Pharmacol 1998; 32:988-994.
32. Dudley C, Keavney B, Casadei B, Conway J, Bird R, Ratcliffe P. Prediction of patient responses to antihypertensive drugs using genetic polymorphisms: investigation of renin-angiotensin system genes. J Hypertens 1996; 14:259-262.
33. Harrap SB, Tzourio C, Cambien F, Poirier O, Raoux S, Chalmers J, et al. The ACE gene I/D polymorphism is not associated with the blood pressure and cardiovascular benefits of ACE inhibition. Hypertension 2003; 42:297-303.
34. Woodiwiss AJ, Nkeh B, Samani NJ, Badenhorst D, Maseko M, Tiago AD, et al. Functional variants of the angiotensinogen gene determine antihypertensive responses to angiotensin-converting enzyme inhibitors in subjects of African origin. J Hypertens 2006; 24:1057-1064.
35. Bonnardeaux A, Davies E, Jeunemaitre X, Fery I, Charru A, Clauser E, et al. Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension. Hypertension 1994; 24:63-69.
36. Mottl AK, Shoham DA, North KE. Angiotensin II type 1 receptor polymorphisms and susceptibility to hypertension: a HuGE review. Genet Med 2008; 10:560-574.
37. Wang WY, Zee RY, Morris BJ. Association of angiotensin II type 1 receptor gene polymorphism with essential hypertension. Clin Genet 1997; 51:31-34.
38. Paukku K, Kalkkinen N, Silvennoinen O, Kontula KK. Lehtonen JY. p100 increases AT1R expression through interaction with AT1R 3'-UTR. Nucleic Acids Res 2008; 36:4474-4487.
39. Backlund M, Paukku K, Daviet L, De Boer RA, Valo E, Hautaniemi S, et al. Posttranscriptional regulation of angiotensin II type 1 receptor expression by glyceraldehyde 3-phosphate dehydrogenase. Nucleic Acids Res 2009; 37:2346-2358.
40. Martin MM, Buckenberger JA, Jiang J, Malana GE, Nuovo GJ, Chotani M, et al. The human angiotensin II type 1 receptor + 1166 A/C polymorphism attenuates microrna-155 binding. J Biol Chem 2007; 282:24262-24269.
41. Sethupathy P, Borel C, Gagnebin M, Grant GR, Deutsch S, Elton TS, et al.Human microRNA-155 on chromosome 21 differentially interacts with its polymorphic target in the AGTR1 3( untranslated region: A mechanism for functional single-nucleotide polymorphisms related to phenotypes. Am J Hum Genet 2007; 81:405-413.